These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 21785750)

  • 21. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.
    Williams-Herman D; Round E; Swern AS; Musser B; Davies MJ; Stein PP; Kaufman KD; Amatruda JM
    BMC Endocr Disord; 2008 Oct; 8():14. PubMed ID: 18954434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
    Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ
    Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis.
    Hou L; Zhao T; Liu Y; Zhang Y
    Exp Ther Med; 2015 Apr; 9(4):1528-1536. PubMed ID: 25780464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in austrian primary care].
    Ludvik B; Daniela L
    Wien Klin Wochenschr; 2011 Apr; 123(7-8):235-40. PubMed ID: 21451952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.
    Williams-Herman D; Engel SS; Round E; Johnson J; Golm GT; Guo H; Musser BJ; Davies MJ; Kaufman KD; Goldstein BJ
    BMC Endocr Disord; 2010 Apr; 10():7. PubMed ID: 20412573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a
    Yazbeck R; Jaenisch S; Squire M; Abbott CA; Parkinson-Lawrence E; Brooks DA; Butler RN
    Sci Rep; 2019 Mar; 9(1):4906. PubMed ID: 30894647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin.
    Kim YA; Yoo WS; Hong ES; Ku EJ; Park KS; Lim S; Cho YM; Park KS; Jang HC; Choi SH
    Diabetes Metab J; 2015 Dec; 39(6):489-97. PubMed ID: 26616595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Letter: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7).
    Kim YA
    Diabetes Metab J; 2015 Oct; 39(5):444-5. PubMed ID: 26566503
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus.
    Yang HK; Kang B; Lee SH; Kim HS; Yoon KH; Cha BY; Cho JH
    Diabetes Metab J; 2015 Aug; 39(4):335-41. PubMed ID: 26301196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal candidates for the switch from glimepiride to sitagliptin to reduce hypoglycemia in patients with type 2 diabetes mellitus.
    Kim HM; Lim JS; Lee BW; Kang ES; Lee HC; Cha BS
    Endocrinol Metab (Seoul); 2015 Mar; 30(1):84-91. PubMed ID: 25325279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes.
    Oh TJ; Jung HS; Bae JH; Kim YG; Park KS; Cho YM; Park KS; Kim SY
    J Korean Med Sci; 2013 Jun; 28(6):881-7. PubMed ID: 23772153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.
    Bloomgarden ZT; Tunceli K; Liu J; Brodovicz KG; Mavros P; Engel SS; Radican L; Chen Y; Rajpathak S; Qiu Y; Brudi P; Fonseca V
    J Diabetes; 2017 Jul; 9(7):677-688. PubMed ID: 27531167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
    Pérez-Monteverde A; Seck T; Xu L; Lee MA; Sisk CM; Williams-Herman DE; Engel SS; Kaufman KD; Goldstein BJ
    Int J Clin Pract; 2011 Sep; 65(9):930-8. PubMed ID: 21849007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study.
    Valensi P; de Pouvourville G; Benard N; Chanut-Vogel C; Kempf C; Eymard E; Moisan C; Dallongeville J
    Diabetes Metab; 2015 Jun; 41(3):231-8. PubMed ID: 25976701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retrospective analysis on the efficacy, safety and treatment failure group of sitagliptin for mean 10-month duration.
    Kim WJ; Park CY; Jeong EH; Seo JY; Seol JS; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Kim SW
    Diabetes Metab J; 2011 Jun; 35(3):290-7. PubMed ID: 21785750
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.